Still, research suggests that it may be an effective strategy for treating metabolic disorders, type 2 diabetes mellitus (T2DM), obesity, and non-alcoholic fatty liver disease, primarily by reducing fat accumulation and inhibiting postprandial insulin secretion (Cunha et al., 2020; Watanabe et al., 2020). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.